Mark Pruzanski
- Hepatology top 1%
- Liver Diseases and Immunity 4
- Liver Disease and Transplantation 1
- Oncology top 1%
- Drug Transport and Resistance Mechanisms 19
- Epidemiology top 1%
- Liver Disease Diagnosis and Treatment 8
- Surgery top 2%
- Cholesterol and Lipid Metabolism 6
-
- Estrogen and related hormone effects 3
-
- Microbial Metabolism and Applications 1
-
- Fibroblast Growth Factor Research 1
- Co-authors
- Roberto PellicciariCharles ThomasKristina SchoonjansJohan AuwerxLuciano AdoriniД. А. ШапироAntonio MacchiaruloAntimo Gioiello
- Cited by
- HepatologyOncologyEpidemiology
- Journals
- Journal of Pharmacology and Experimental Therapeutics (3 papers)Journal of Hepatology (3 papers)ACS Medicinal Chemistry Letters (2 papers)
- Partner nations
- ItalyUnited StatesFrance
In The Last Decade
Mark Pruzanski
23 papers receiving 5.1k citations
Hit Papers
Peers
Comparison fields: 5 of 106
- Hepatology 870
- Oncology 2.5k
- Epidemiology 2.2k
- Endocrinology, Diabetes and Metabolism 888
- Surgery 1.7k
Countries citing papers authored by Mark Pruzanski
This map shows the geographic impact of Mark Pruzanski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Pruzanski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Pruzanski more than expected).
Fields of papers citing papers by Mark Pruzanski
This network shows the impact of papers produced by Mark Pruzanski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Pruzanski. The network helps show where Mark Pruzanski may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Pruzanski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 52 | |
| 2 | 2013 | 189 | |
| 3 | Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Diseasebreakdown → | 2013 | 767 |
| 4 | 2013 | 35 | |
| 5 | 2012 | 34 | |
| 6 | 2012 | 214 | |
| 7 | 2012 | 33 | |
| 8 | 2011 | 47 | |
| 9 | The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the faresoid C receptor agonist obeticholic acid in PBC | 2011 | 6 |
| 10 | 2011 | 13 | |
| 11 | Functional Characterization Of The Semi-Synthetic Bile Acid Derivative Int-767, A Dual Fxr And Tgr5 Agonist | 2010 | 1 |
| 12 | 2010 | 156 | |
| 13 | 2010 | 2 | |
| 14 | TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasisbreakdown → | 2009 | 1439 |
| 15 | 2009 | 138 | |
| 16 | 2009 | 218 | |
| 17 | Targeting bile-acid signalling for metabolic diseasesbreakdown → | 2008 | 1098 |
| 18 | 2005 | 164 | |
| 19 | 2005 | 162 | |
| 20 | 2005 | 156 |
About Mark Pruzanski
Mark Pruzanski is a scholar working on Oncology, Hepatology, Epidemiology, Pharmacology and Surgery, having authored 23 papers that have together received 5.2k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (19 papers), Liver Disease Diagnosis and Treatment (8 papers), Cholesterol and Lipid Metabolism (6 papers), Liver Diseases and Immunity (4 papers), Estrogen and related hormone effects (3 papers), Liver Disease and Transplantation (1 paper), Microbial Metabolism and Applications (1 paper) and Fibroblast Growth Factor Research (1 paper). The work is most often cited by research in Hepatology (870 citations), Oncology (2.5k citations), Epidemiology (2.2k citations), Endocrinology, Diabetes and Metabolism (888 citations) and Surgery (1.7k citations). Mark Pruzanski has collaborated with scholars based in Italy, United States and France. Frequent co-authors include Roberto Pellicciari, Charles Thomas, Kristina Schoonjans, Johan Auwerx, Luciano Adorini, Д. А. Шапиро, Antonio Macchiarulo, Antimo Gioiello, Giovanni Rizzo and Julien Oury. Their work appears in journals such as Journal of Pharmacology and Experimental Therapeutics, Journal of Hepatology, ACS Medicinal Chemistry Letters, Diabetes and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.